Vertaling van "treatment and initial " (Nederlands → Frans) :

Gait analysis after initial non-operative treatment for clubfeet: intermediate term follow up at age 5 We conducted gait analysis following initial nonoperative clubfoot treatment to compare lower extremity kinematic (eg, ankle motion) and kinetic (eg, ankle power) characteristics between patients treated as infants with Ponseti casting or French phys [ publicatie ] [ 4/03/2012 ]
Concurrent musculoskeletal dynamics and finite element analysis predicts altered gait patterns to reduce foot tissue loading Current computational methods for simulating locomotion have primarily used muscle-driven multibody dynamics, in which neuromuscular control is optimized. [ publication ] [ 4/03/2012 ]

Boutitie F, Pinede L, Schulman S et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participant’s data from seven trials.
Oudega R, Van Weert H, Stoffers H et al. NHG-Standaard: Diepe veneuze trombose.

Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72(5):4265-73.
Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent

Shingler S, Robertson L, Boghossian S, Stewart M. Compression stockings for the initial treatment of varicose veins in patients without venous ulceration.
Nogaro MC, Pournaras DJ, Prasannan C et al. Varicose veins.

P.August: Initial treatment of hypertension N Engl J Med 348 : 610-617(2003)
P.August: Initial treatment of hypertension. N Engl J Med 348 : 610-617(2003)

348, 639-641 (2003) P.August: Initial treatment of hypertension.
348, 583-592 (2003) E.D.F. Frohlich (Editorial) : Treating hypertension - What are we to believe ?

Novartis is helping patients in the developing world through key initiatives focused on neglected diseases, especially malaria, leprosy, dengue fever and treatment-resistant tuberculosis.
Novartis aide les malades des pays en voie de développement par le biais de projets importants centrés sur des maladies négligées, en particulier le paludisme, la lèpre, la fièvre de dengue et la tuberculose résistant aux traitements.

In the US, Novartis has teamed up with a New Jersey healthcare system for over 30 years to aid cancer patients and their families from initial treatment through survivorship.
Aux Etats-Unis, depuis plus de 30 ans, Novartis s’est associé à un système de santé au New Jersey pour accompagner des malades du cancer et leur famille, de la phase initiale du traitement jusqu’au terme de la maladie.

Malaria kills a child under age five every 30 seconds in Africa Only 10% of R&D funds are used for research into 90% of the world’s health problems The NITD was granted USD 20 million in 2006 by the Wellcome Trust, the Singapore Economic Development Board and Medicines for Malaria Venture to initiate joint research on malaria Leprosy has dropped by over 90% since 1985 Deliveries for Coartem have climbed from four million treatments in 2004 to over 60 million in 2006
En Afrique, la malaria tue un enfant de moins de cinq ans toutes les 30 secondes Seuls 10% des fonds consacrés à la recherche sont investis dans les maladies qui représentent 90% des problèmes de santé dans le monde En 2006, l’Institut Novartis pour les maladies tropicales a obtenu du Wellcome Trust, du Singapore Economic Development Board et de Medicines for Malaria Venture USD 20 millions pour initier un programme commun de recherche sur la malaria Depuis 1985, la lèpre a diminué de plus de 90% Entre 2004 et 2006, les livraisons de Coartem sont passées de 4 millions à plus de 60 millions de traitements

“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis. “We are proud to be a part of this innovative effort to support a healthier world”.
“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis.